Guide to Drug Dosage in Hepatic Disease

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Clinical Pharmacokinetics

• Publication date

  1988-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00003088-198815060-00004PMID 3072141
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver.

  2009cited by this paper
• Cimetidine Kinetics and Dynamics in Patients with Severe Liver Disease

  2007cited by this paper
• Bioavailability and elimination of nitrendipine in liver disease

  2006cited by this paper
• Effect of liver failure on the pharmacokinetics of cyclophosphamide

  2004cited by this paper
• Effect of cirrhosis and renal failure on the kinetics of clotiazepam

  2004cited by this paper
• The effects of age and chronic liver disease on the elimination of temazepam

  2004cited by this paper
• Naproxen disposition in patients with alcoholic cirrhosis

  2004cited by this paper
• Pharmacokinetics of furosemide in patients with hepatic cirrhosis

  2004cited by this paper
• Pharmacokinetics of ceftazidime in patients with biliary tract disease

  2004cited by this paper
• Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease

  2004cited by this paper
• The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon

  2004cited by this paper
• Cirrhosis of the liver markedly impairs the elimination of mexiletine

  2004cited by this paper
• Assessment of drug metabolism in hepatic disease: Comparison of plasma kinetics of oral cyclobarbital and the intravenous aminopyrine breath test

  2004cited by this paper
• Single-dose kinetics of primidone in acute viral hepatitis

  2004cited by this paper
• Cimetidine disposition in patients with Laennec's cirrhosis during multiple dosing therapy

  2004cited by this paper
• Pharmacokinetics of cimetidine in advanced cirrhosis

  2004cited by this paper
• Pharmacokinetic study of chloramphenicol in patients with liver disease

  2004cited by this paper
• Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide

  2004cited by this paper
• Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis

  2004cited by this paper
• Pharmacokinetics of tocainide in patients with combined hepatic and renal dysfunction

  2004cited by this paper
• Vecuronium in Alcoholic Liver Disease: A Pharmacokinetic and Pharmacodynamic Analysis

  1988cited by this paper
• A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls.

  1987cited by this paper
• Single oral dose pharmacokinetics of bisoprolol 10 mg in liver disease.

  1987cited by this paper
• Drug metabolism in patients with liver disease.

  1987cited by this paper
• Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity.

  1987cited by this paper
• Pharmacokinetics and Haemodynamic Effects of Nisoldipine in Patients with Liver Cirrhosis

  1987cited by this paper
• mechanism of the excessive sedative response of cirrhotics to benzodiazepines: Model experiments with triazolam

  1987cited by this paper
• Pharmacokinetics of Esmolol in Hepatic Disease

  1987cited by this paper
• Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis.

  1986cited by this paper
• Reduction of Paracetamol and Aspirin Metabolism During Viral Hepatitis

  1986cited by this paper
• Nifedipine: Kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration

  1986cited by this paper
• Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency.

  1986cited by this paper
• Encainide disposition in patients with chronic cirrhosis

  1986cited by this paper
• Pefloxacin kinetics in cirrhosis

  1985cited by this paper
• Altered Amitriptyline Kinetics in a Depressed Patient with Porto-Caval Anastomosis

  1985cited by this paper
• Safety and pharmacokinetics of ceftazidime in patients with chronic hepatic dysfunction.

  1985cited by this paper
• Triamterene kinetics and dynamics in cirrhosis

  1984cited by this paper
• Decreased Binding of Verapamil to Plasma Proteins in Patients with Liver Disease

  1984cited by this paper
• Alprazolam Pharmacokinetics in Alcoholic Liver Disease

  1984cited by this paper
• Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure).

  1984cited by this paper
• Effect of hepatic dysfunction on oral cyclosporin pharmacokinetics in marrow transplant patients.

  1984cited by this paper
• Effects of cirrhosis on kinetics of aztreonam

  1984cited by this paper
• Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in cirrhosis of the liver.

  1984cited by this paper
• Pharmacokinetics of Nitrendipine in Patients with Renal Failure: Comparison to Normal Subjects

  1984cited by this paper
• Ranitidine disposition and systemic availability in hepatic cirrhosis

  1984cited by this paper
• Diphenhydramine disposition in chronic liver disease

  1984cited by this paper
• Disposition and Metabolism of Metronidazole in Patients with Liver Failure

  1984cited by this paper
• Steady‐State Pharmacokinetics of Nitrendipine in Hepatic Insufficiency

  1984cited by this paper
• Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model.

  1984cited by this paper
• Drug administration in hepatic disease.

  1983cited by this paper
• Effects of hepatic function on vancomycin clinical pharmacology

  1983cited by this paper
• [Pharmacokinetics of cimetidine in ascitic cirrhotics].

  1983cited by this paper
• Acetaminophen in chronic liver disease

  1983cited by this paper
• [Pharmacokinetics and metabolism of acetaminophen in normal, alcoholic and cirrhotic subjects].

  1983cited by this paper
• [Pharmacokinetics of gentamicin in the decompensed alcoholic cirrhotic patient. Therapeutic consequences].

  1983cited by this paper
• Hepatic encephalopathy and altered cimetidine kinetics

  1983cited by this paper
• The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease.

  1983cited by this paper
• Ibuprofen and sulindac kinetics in alcoholic liver disease

  1983cited by this paper
• Pharmacokinetics of isosorbide-5-mononitrate after oral and intravenous administration in patients with liver cirrhosis: first results.

  1983cited by this paper
• [Pharmacokinetics of intravenous ranitidine and its effect on gastric acid secretion stimulated by pentagastrin in the cirrhotic].

  1983cited by this paper
• Pharmacokinetics of oral brotizolam in patients with liver cirrhosis.

  1983cited by this paper
• Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage

  1983cited by this paper
• Pharmacokinetics of triamterene.

  1983cited by this paper
• Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam.

  1983cited by this paper
• Clinical Experience with Atenolol in Patients with Chronic Liver Disease

  1983cited by this paper
• Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis

  1983cited by this paper
• Mezlocillin kinetics in hepatic insufficiency

  1983cited by this paper
• Thiopental Pharmacokinetics in Patients with Cirrhosis

  1983cited by this paper
• [Effect of various types of liver diseases on the behavior of cefoperazone].

  1983cited by this paper
• Prednisolone pharmacokinetics and protein-binding in patients with portosystemic shunt.

  1983cited by this paper
• Plasma concentrations and central nervous system effects of the new hypnotic agent zopiclone in patients with chronic liver disease.

  1983cited by this paper
• PHARMACOKINETICS OF ATRACURIUM IN ACUTE HEPATIC FAILURE (WITH ACUTE RENAL FAILURE)

  1983cited by this paper
• Altered quinidine disposition in a patient with chronic active hepatitis

  1982cited by this paper
• Pharmacokinetic studies of cefuroxime in patients with liver cirrhosis.

  1982cited by this paper
• Altered disposition and availability of cimetidine in liver cirrhotic patients.

  1982cited by this paper
• Furosemide disposition in cirrhosis

  1982cited by this paper
• Oral and intravenous pharmacokinetics of cimetidine in liver cirrhosis.

  1982cited by this paper
• Comparative Serum Prednisone and Prednisolone Concentrations Following Administration to Patients with Chronic Active Liver Disease

  1982cited by this paper
• Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis.

  1982cited by this paper
• Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis.

  1982cited by this paper
• Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine.

  1982cited by this paper
• Pharmacokinetics of Erythromycin in Normal and Alcoholic Liver Disease Subjects

  1982cited by this paper
• Furosemide disposition in cirrhotic patients.

  1981cited by this paper
• Age, disease, and cimetidine disposition in healthy subjects and chronically ill patients

  1981cited by this paper
• Methadone disposition in patients with chronic liver disease

  1981cited by this paper
• Decreased extrarenal clearance of cefoperazone in hepatocellular diseases.

  1981cited by this paper
• Clinical pharmacokinetics of chlordiazepoxide in patients with alcoholic hepatitis

  1981cited by this paper
• Cimetidine clearance and bioavailability in hepatic cirrhosis

  1981cited by this paper
• Pharmacokinetics of Metoprolol in Patients with Hepatic Cirrhosis

  1981cited by this paper
• Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects

  1981cited by this paper
• Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.

  1981cited by this paper
• Normal metabolism of morphine in cirrhosis.

  1981cited by this paper
• Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics

  1980cited by this paper
• Naproxen disposition in hepatic and biliary disorders.

  1980cited by this paper
• Drug pharmacokinetics in cardiac and hepatic disease.

  1980cited by this paper
• Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt

  1980cited by this paper
• Pharmacokinetics and metabolism of theophylline in patients with liver diseases.

  1980cited by this paper
• [Metabolism and kinetics of ampicillin elimination in cirrhosis. Therapeutical consequences (author's transl)].

  1980cited by this paper
• Impaired elimination of caffeine in cirrhosis

  1980cited by this paper
• Fazadinium pharmacokinetics in patients with liver disease.

  1980cited by this paper

• Camel urine as a potential source of bioactive molecules showing their efficacy against pathogens: A systematic review

  2024cites this paper
• Diseases of the Hepatobiliary System

  2020cites this paper
• 2 Pharmacokinetic Principles

  2019cites this paper
• University of Washington

  2019cites this paper
• Variations of pharmacokinetics of drugs in patients with cirrhosis

  2016cites this paper
• Pharmacokinetic variations in cancer patients with liver dysfunction: applications and challenges of pharmacometabolomics

  2016cites this paper
• A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child–Pugh Classification

  2015cites this paper
• The assessment of the probability for the surgical treatment of colorectal cancer with concomitant liver cirrhosis

  2014cites this paper
• Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der

  2012cites this paper
• Pharmacokinetic Principles

  2011cites this paper
• Liver fibrosis impairs hepatic pharmacokinetics of liver transplant drugs in the rat model.

  2010cites this paper
• Pharmacokinetic Changes of Psychotropic Drugs in Patients with Liver Disease

  2009cites this paper
• Pharmacokinetics and dosage adjustment in patients with renal dysfunction

  2008cites this paper
• Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury

  2008cites this paper
• A 4 – Arzneimitteltherapie bei Patienten mit Leberinsuffizienz

  2007cites this paper
• Palliation and Liver Failure: Palliative Medications Dosage Guidelines

  2007cites this paper
• An overview of psychiatric issues in liver disease for the consultation-liaison psychiatrist.

  2006cites this paper
• Dose Adaptation of Antineoplastic Drugs in Patients with Liver Disease

  2006cites this paper
• Dose Adaptation of Drugs in Patients with Liver Disease

  2004cites this paper
• Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses

  2004cites this paper
• Point prevalence of drug prescriptions for elderly and non-elderly inpatients in a teaching hospital

  2004cites this paper
• Pharmacokinetics of the anti-inflammatory drug ximoprofen in healthy subjects and in disease states

  2004cites this paper
• Dosisanpassung bei Leberinsuffizienz

  2003cites this paper
• Pharmacokinetic and Pharmacodynamic Considerations When Treating Patients with Sepsis and Septic Shock

  2002cites this paper
• Pharmacokinetics and Pharmacodynamics in Cirrhosis

  2002cites this paper
• Impairment of the metabolism of dipyrone in asymptomatic carriers of the hepatitis-B virus does not occur in rapid acetylators

  2001cites this paper
• Grundlagen der Pharmakokinetik und pharmakokinetische Besonderheiten im Alter

  2000cites this paper
• Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients.

  2000cites this paper
• Monitoring drug therapy in the intensive care unit.

  2000cites this paper
• Effects of Liver Disease on Pharmacokinetics

  1999cites this paper
• Effect of hepatic insufficiency on pharmacokinetics and drug dosing

  1998cites this paper
• Review of pharmacokinetics and pharmacodynamics of antimicrobial agents.

  1998cites this paper
• Clinical importance of non‐genetic and genetic cytochrome P450 function tests in liver disease

  1998cites this paper
• [Perfusion and metabolism of liver and splanchnic nerve area under sevoflurane anesthesia].

  1998cites this paper
• Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6

  1998cites this paper
• Durchblutung und Metabolismus von Leber und Splanchnikusgebiet unter Sevofluran

  1998cites this paper
• [Adjusting dosage of drugs in patients with kidney or liver failure].

  1998cites this paper
• Hepatobiliary excretion of bile acids and rose bengal in streptozotocin-induced and genetic diabetic rats.

  1997cites this paper
• Impairment of the metabolism of dipyrone in asymptomatic carriers of the hepatitis B virus

  1997cites this paper
• Pharmacokinetics of Dolasetron after Oral and Intravenous Administration of Dolasetron Mesylate in Healthy Volunteers and Patients with Hepatic Dysfunction

  1997cites this paper
• The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans.

  1997cites this paper
• Role of Viral Infections in the Induction of Adverse Drug Reactions

  1997cites this paper
• Hepatic drug clearance in patients with mild cystic fibrosis

  1996cites this paper
• Effects of liver diseases on drug metabolism.

  1996cites this paper
• Pharmakokinetik als Grundlage der Therapie

  1996cites this paper
• Pharmakokinetische Besonderheiten bei kritischen Intensivpatienten

  1996cites this paper
• Assessment of Liver Metabolic Function

  1994cites this paper
• Is debrisoquine hydroxylation modified during acute viral hepatitis?

  1994cites this paper
• Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction.

  1994cites this paper
• Drug-Induced Hepatic Disorders

  1993cites this paper
• Clinical Pharmacokinetics of Newer Antibacterial Agents in Liver Disease

  1993cites this paper
• Oral disposition kinetics of ofloxacin in patients with compensated liver cirrhosis.

  1992cites this paper
• Pharmacokinetic Optimisation of Antiemetic Therapy

  1992cites this paper
• Pharmacokinetics of trapidil (Rocornal) in patients with chronic liver disease.

  1992cites this paper
• Subject Selection and Management in Bioequtvalence Studies

  1992cites this paper
• Clinical Pharmacokinetics in Patients with Liver Disease

  1991cites this paper
• [The effect of disease states on the pharmacokinetics of drugs. 2. Liver and biliary diseases].

  1991cites this paper
• Enhanced hepatic drug clearance in patients with cystic fibrosis.

  1990cites this paper
• Conjugation pathways in liver disease.

  1990cites this paper
• Disease States and Drug Pharmacokinetics

  1989cites this paper